New Guideline Puts Some at the Front of the Line for GLP-1, SGLT2 Drugs
In a new “living” guideline, intended to keep pace with the rapidly growing evidence base for these emerging drugs, an international expert group said that SGLT2 inhibitors and GLP-1 receptor agonists both get a weak recommendation against use in type 2 diabetes patients at low risk of cardiovascular and kidney…